Patrick Bidulka
BSc MSc
Research Fellow
LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom
My research explores how we can use routinely collected health data to investigate comparative treatment effects where we lack randomised evidence. I focus on comparing alternative antidiabetic treatments among people with type 2 diabetes, as well as alternative heart attack treatments among people with kidney disease.
I completed an MSc in epidemiology at London School of Hygiene & Tropical Medicine, and a BSc in pharmacology and economics at McGill University in Montreal, Canada. Alongside my work, I am a PhD candidate.
Prior to joining the LSHTM, I worked at McGill Global Health Programs and the Population Health Research Institute (PHRI) in Hamilton, Canada. I continue to collaborate with researchers at PHRI.
Affiliations
Centres
Teaching
I teach on the following MSc modules and short courses:
- Extended Epidemiology
- Statistical Methods in Epidemiology
- Epidemiology in Practice
- Analysis of Electronic Health Records
- Professional Certificate in Pharmacoepidemiology & Pharmacovigilance
I supervise summer projects related to non-communicable disease management and treatment using electronic health records for the following master's courses:
- MSc Epidemiology
- MSc Medical Statistics
- MSc Health Data Science
I also a co-lead and supervise for the Health Data Research (HDR)-UK Black Internship Programme hosted at LSHTM, which aims to reduce the underrepresentation of Black people within the health data science sector.
Research
I am currently involved with several pharmacoepidemiology and health services projects:
- Improving acute cardiac care for patients with kidney disease through linkage of national audits in the UK (IAC-CKD)
- Personalised Medicine for Intensification of Treatment (PERMIT): the case for type 2 diabetes mellitus
- Quality and equity in cardiac care in chronic kidney disease: the promise of big data (QECKD)
- Organised Stroke Care Across Income Levels (OSCAIL)
- Describe services and treatments for type 2 diabetes, cardiovascular disease, and kidney disease in the UK;
- Identify potential inequities in the delivery of these health care services/treatments;
- Compare alternative treatment strategies for type 2 diabetes and cardiovascular disease where clinical equipoise persists.